What is Great Novel Therapeutics Biotech & Medicals EBIT per Share?
Great Novel Therapeutics Biotech & Medicals's EBIT per Share for the
six
months ended in Dec. 2023 was NT$-0.69.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-1.65.
During the past 3 years, the average EBIT per Share Growth Rate was -3.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 6.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
ROCO:7427'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -3.2 Med: -2.9 Max: 19.8
Current: -3.2
During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Great Novel Therapeutics Biotech & Medicals was 19.80% per year. The lowest was -3.20% per year. And the median was -2.90% per year.
ROCO:7427's 3-Year EBIT Growth Rate is ranked worse than 57.72% of 1301
companies
in the Biotechnology industry
Industry Median: 3.4
vs ROCO:7427: -3.20
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Great Novel Therapeutics Biotech & Medicals EBIT per Share Chart
Great Novel Therapeutics Biotech & Medicals Annual Data
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-1.65
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Great Novel Therapeutics Biotech & Medicals (ROCO:7427) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Great Novel Therapeutics Biotech & Medicals EBIT per Share Related Terms
Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Business Description
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.
Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ROCO:7427 has been successfully added to your 